BioSpace News Archive

Advances in endoscopic techniques have expanded the scope of different sinus dilation devices market in ENT care.

The demand within the global market for prenatal vitamin supplements has been rising on account of the focus given on the health of pregnant women, finds Transparency Market Research.

Financial Results. Net losses from the same quarter last year decreased 11.7%, from $1,135,420 in Q1 2019 to $1,002,868 in Q1 2020, primarily attributed to a decrease in selling, general, and administration expenses.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the results from its Annual General Meeting (“AGM”) held today, May 15, 2020.

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it will release first quarter 2020 financial results and a Company update after the market closes on Wednesday, May 20, 2020

The COVID-19 pandemic triggered urgent testing needs globally. Given the nature and magnitude of this public health emergency in the USA, testing laboratories in the private sector are “all hands on deck” with frontline medical workers in large scale diagnostics testing for COVID-19 presence.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the U.S. Food and Drug Administration (FDA) has approved QINLOCK™ (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world’s only in vivo Intravaginal Culture System, today announced financial results for the quarter ended March 31, 2020.

Nxt-ID, Inc. (NASDAQ: NXTD) (the “Company”), a provider of healthcare devices and services, announces results for the three months ended March 31, 2020.

Correvio Pharma Corp. (“Correvio” or the “Company”) (NASDAQ: CORV) (TSX: CORV), today announced the results of voting on matters considered at its annual general and special meeting (the “Meeting”) of Correvio shareholders and holders of options, restricted share units and phantom share units (collectively, the “Securityholders”) which took place in a virtual format earlier today.